Certara (CERT) to Release Quarterly Earnings on Wednesday

Certara (NASDAQ:CERTGet Free Report) is anticipated to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect Certara to post earnings of $0.13 per share and revenue of $99.13 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Certara Trading Down 4.7 %

CERT opened at $12.55 on Tuesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company’s 50 day simple moving average is $12.34 and its two-hundred day simple moving average is $11.63. Certara has a 1-year low of $9.41 and a 1-year high of $19.87. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -62.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57.

Analyst Ratings Changes

A number of research firms have weighed in on CERT. Robert W. Baird decreased their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Barclays cut their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.92.

Read Our Latest Stock Report on Certara

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

Featured Stories

Earnings History for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.